39586257
abacavir, dolutegravir, lamivudine
(Triumeq)
- Brand: Triumeq
- NRTIs
Annotations:
- abacavir (ABC) & lamivudine (3TC) are both NRTIs. The former is also used for HBV tx.
- INSTI
Annotations:
- dolutegravir (DTG) is the integrase inhibitor
- Tablets ONLY
- 600 mg abacavir
- 50 mg dolutegravir
- 300 mg lamivudine
- 600 mg abacavir
- NRTIs
- Combination Anti-Retroviral
- HIV Treatment
- helps prevent resistance
Annotations:
- HIV is a fast adapting virus. Using multiple drugs with different MOAs helps prevent resistance from developing to a single agent.
- HIV Treatment
- Indications
- HIV-1
infection
Annotations:
- 1T QD
- adult & pediatrics > 40
kg
Annotations:
- if used in combination with UGT1A or CYP-3A inducers, an additional 50 mg of dolutegravir should be taken 12 hours after Triumeq
- HIV-1
infection
- Monitoring
- LFT
Annotations:
- many HIV drugs can adversely affect the liver
- CD4+
Annotations:
- Monitoring the progress of the disease
- LFT
- Contraindications
- concommitant
dofetilide
- Severe Hepatic
Impairment
- HLA-B*5701
- 1st trimester of
pregnancy
- St, John's Wort
- concommitant
dofetilide
- ADEs
- hypersensitivity
Annotations:
- severe rash, fever, malaise, fatigue, muscle/joint aches, blisters, conjunctivitis, facial edema, hepatitis, angioedema
- lactic acidosis
- liver toxicity
- immune reconstitution
syndrome
- Most Common
- sleep
disturbances
- tiredness
- headache
- sleep
disturbances
- hypersensitivity
- Patient Consultation
- Calcium, Zinc, or Iron
containing products
Annotations:
- take 2 hours before or 6 hours after -includes antacids
- do NOT double dose
Annotations:
- if dose is missed, take ASAP unless too close to next dose
- Calcium, Zinc, or Iron
containing products
Want to create your own Mind Maps for free with GoConqr? Learn more.